IL304600A - Methods for treating cancer using anti-tigit antibodies in combination with anti-pd1 antibodies - Google Patents

Methods for treating cancer using anti-tigit antibodies in combination with anti-pd1 antibodies

Info

Publication number
IL304600A
IL304600A IL304600A IL30460023A IL304600A IL 304600 A IL304600 A IL 304600A IL 304600 A IL304600 A IL 304600A IL 30460023 A IL30460023 A IL 30460023A IL 304600 A IL304600 A IL 304600A
Authority
IL
Israel
Prior art keywords
antibodies
methods
combination
cancer treatment
tigit
Prior art date
Application number
IL304600A
Other languages
English (en)
Hebrew (he)
Inventor
Tong Zhang
Liu Xue
Qi Liu
Min Wei
Kang Li
Yunxia Zuo
Original Assignee
Beigene Switzerland Gmbh
Tong Zhang
Liu Xue
Qi Liu
Min Wei
Kang Li
Yunxia Zuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh, Tong Zhang, Liu Xue, Qi Liu, Min Wei, Kang Li, Yunxia Zuo filed Critical Beigene Switzerland Gmbh
Publication of IL304600A publication Critical patent/IL304600A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL304600A 2021-01-21 2023-07-19 Methods for treating cancer using anti-tigit antibodies in combination with anti-pd1 antibodies IL304600A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN2021073083 2021-01-21
CN2021073308 2021-01-22
CN2021074141 2021-01-28
CN2021074644 2021-02-01
CN2021075310 2021-02-04
CN2021091822 2021-05-05
CN2021109322 2021-07-29
PCT/CN2022/072869 WO2022156726A1 (en) 2021-01-21 2022-01-20 Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies

Publications (1)

Publication Number Publication Date
IL304600A true IL304600A (en) 2023-09-01

Family

ID=82548518

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304600A IL304600A (en) 2021-01-21 2023-07-19 Methods for treating cancer using anti-tigit antibodies in combination with anti-pd1 antibodies

Country Status (13)

Country Link
US (1) US20230391883A1 (enExample)
EP (1) EP4281189A4 (enExample)
JP (1) JP2024504331A (enExample)
KR (1) KR20230158464A (enExample)
CN (1) CN117177770A (enExample)
AU (1) AU2022211109A1 (enExample)
BR (1) BR112023014582A2 (enExample)
CO (1) CO2023009626A2 (enExample)
IL (1) IL304600A (enExample)
MX (1) MX2023008597A (enExample)
PE (1) PE20240659A1 (enExample)
TW (1) TW202243691A (enExample)
WO (1) WO2022156726A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115746144B (zh) * 2022-09-02 2026-01-02 安徽瀚海博兴生物技术有限公司 抗tigit-pd1双特异性抗体及其应用
CN121219319A (zh) * 2023-06-27 2025-12-26 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
CN121003695A (zh) * 2024-05-24 2025-11-25 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI888366B (zh) * 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
TWI816729B (zh) * 2017-12-30 2023-10-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
MX2020008882A (es) * 2018-02-26 2021-01-08 Genentech Inc Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用

Also Published As

Publication number Publication date
CN117177770A (zh) 2023-12-05
EP4281189A4 (en) 2025-01-08
JP2024504331A (ja) 2024-01-31
TW202243691A (zh) 2022-11-16
BR112023014582A2 (pt) 2023-09-26
AU2022211109A1 (en) 2023-09-07
EP4281189A1 (en) 2023-11-29
MX2023008597A (es) 2023-08-10
PE20240659A1 (es) 2024-04-04
KR20230158464A (ko) 2023-11-20
CO2023009626A2 (es) 2023-09-08
WO2022156726A1 (en) 2022-07-28
US20230391883A1 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
IL313807A (en) Claudin 18 antibodies and methods for cancer treatment
MX2024013523A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
MY205760A (en) Humanized antibodies against c-kit
ZA202204423B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
IL279251A (en) Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
IL275940A (en) Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment
MY204673A (en) Humanized anti-sirp antibodies
GEP20217317B (en) Combination therapy for the treatment of cancer
EP4281189A4 (en) METHODS OF TREATING CANCER USING ANTI-TIGIT ANTIBODIES IN COMBINATION WITH ANTI-PD1 ANTIBODIES
MX2021000439A (es) Anticuerpos de antigeno anti-tf humanizado.
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
IL286337A (en) Cancer treatment with her2xcd3 bispecific antibodies in combination with anti-her2 mab
IL280830A (en) Bracelets for use in cancer treatment methods
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
LT4340842T (lt) Sotorasibas, skirtas naudoti vėžio gydymui
ZA202204252B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HK40103626A (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
IL307556A (en) Cancer treatment methods using antibodies against TIGIT
IL312813A (en) Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
EP4061844A4 (en) METHODS OF TREATING CANCER WITH ANTI-OX40 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY AGENTS
HK40072365A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
PL4004056T3 (pl) Przeciwciała anty-lewis y i ich zastosowanie w terapii nowotworów
HK40072366A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
IL279484A (en) Methods for improving response to anti-LIF antibody therapy in individuals with cancer